ALZN

Alzamend Neuro Inc

Stock NASDAQ – Stock Market Prices, News & Analysis

Alzamend Neuro Inc is a biotechnology company engaged in the development of novel treatments for neurological diseases, particularly Alzheimer's disease.

$ 1.08
2.70 %

Alzamend Neuro Inc

$ 1.08
2.70 %
ALZN

Alzamend Neuro Inc is a biotechnology company engaged in the development of novel treatments for neurological diseases, particularly Alzheimer's disease.

Price history of Alzamend Neuro Inc
Price history of Alzamend Neuro Inc

Performance & Momentum

6 Months 54.24 %
1 Year 81.87 %
3 Years 99.85 %
5 Years 99.99 %

Strategic Analysis

Alzamend Neuro Inc • 2026

Alzamend Neuro Inc positions itself in the American biotechnology sector with a niche focus on the development of innovative treatments for neurological diseases, particularly Alzheimer's disease. Its model relies on advanced research expertise in a medical field with a significant unmet need, despite a very challenging financial and stock market history.

Strengths
  • Clear specialization in neurology, providing targeted scientific expertise
  • Value potential linked to a neurodegenerative disease with high medical and commercial stakes
  • Positioning in a dynamic biotechnology market in the United States
Weaknesses
  • Significantly deteriorated stock performance over several years, reflecting operational or financial difficulties
  • Lack of recent news indicating a relaunch or major advancement
Momentum

The momentum is currently very weak, reinforced by a prolonged downward trend across all available time horizons. This setup suggests extreme caution and a risky profile, requiring clear catalysts to consider a trend reversal.

Similar stocks to Alzamend Neuro Inc

Was this page helpful?

Your feedback helps us improve our research.

Take control
of your investments

Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.

  • Real-time multi-portfolio tracking
  • AI analysis of your positions
  • Counter your cognitive biases
Anantys Invest on iPhone